We are living through an unprecedented era of new technology development in virtually all sectors of the pharmaceutical industry, most notably electronics/digital technologies, healthcare, manufacturing, consumer practices, and transportation. Ten years ago, who would have thought:
In the health sciences sector, we are witnessing transformational advances in how we treat disease. Scientists are now able to utilize viruses to genetically engineer T-cells to kill specific tumor cells, traditional batch development, and manufacturing processes are giving way to smaller footprints, much more flexible continuous and modular technologies, and something called 3-D printing is now being utilized to manufacture FDA approved drugs.
At the 2017 ISPE Annual Meeting in San Diego on 29 October – 1 November, our Innovation Forum educational track will feature seven exciting sessions that will speak to a variety of the most interesting and impactful innovative technologies in the world today, including some of the ones mentioned above. The session titles below speak to the diversity of topics included in the Innovation Forum:
Join us at some or all of the Innovation Forum sessions. You won’t be disappointed.
The 2017 ISPE Annual Meeting & Expo offers a unique experience, built to expand your professional education and increase your exposure to regulators and industry thought leaders from around the world. Education highlights include:
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...